North American Vaccine, Baxter, BioChem deal

The companies reduced by $0.27 to $6.73 the per-share consideration NVX shareholders will receive from BAX under BAX's proposed acquisition

Read the full 201 word article

How to gain access

Continue reading with a
two-week free trial.